Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ: RXRX · Real-Time Price · USD
3.670
-0.100 (-2.65%)
At close: Feb 27, 2026, 4:00 PM EST
3.653
-0.017 (-0.45%)
After-hours: Feb 27, 2026, 7:57 PM EST

Recursion Pharmaceuticals Stock Forecast

Stock Price Forecast

The 5 analysts that cover Recursion Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $7.20, which forecasts a 96.19% increase in the stock price over the next year. The lowest target is $5.00 and the highest is $11.

Price Target: $7.20 (+96.19%)
Analyst Consensus: Buy
TargetLowAverageMedianHigh
Price$5.00$7.20$6.00$11
Change+36.24%+96.19%+63.49%+199.73%

Analyst Ratings

The average analyst rating for Recursion Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

RatingSep '25Oct '25Nov '25Dec '25Jan '26Feb '26
Strong Buy111111
Buy111221
Hold222223
Sell000000
Strong Sell000000
Total444555

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
B of A Securities
B of A Securities
Hold
Maintains
$7$6
HoldMaintains$7$6+63.49%Feb 26, 2026
Needham
Needham
Strong Buy
Reiterates
$8
Strong BuyReiterates$8+117.98%Feb 26, 2026
JP Morgan
JP Morgan
Buy
Upgrades
$10$11
BuyUpgrades$10$11+199.73%Dec 17, 2025
Needham
Needham
Strong Buy
Reiterates
$8
Strong BuyReiterates$8+117.98%Sep 11, 2025
Needham
Needham
Strong Buy
Reiterates
$8
Strong BuyReiterates$8+117.98%Jul 8, 2025
More Analyst Ratings

Financial Forecast

Revenue This Year
84.35M
from 74.68M
Increased by 12.95%
Revenue Next Year
159.12M
from 84.35M
Increased by 88.63%
EPS This Year
-1.16
from -1.44
EPS Next Year
-1.00
from -1.16
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026FY 2027
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026Dec 31, 2027
Revenue
10.18M39.84M44.58M58.84M74.68M84.35M159.12M
Revenue Growth
156.89%291.46%11.88%32.00%26.92%12.95%88.63%
EPS
-1.49-1.36-1.58-1.69-1.44-1.16-1.00
EPS Growth
-------
Forward PE
-------
No. Analysts
-----128
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue20262027
High116.6M336.0M
Avg84.4M159.1M
Low59.9M79.8M

Revenue Growth

Revenue Growth20262027
High
56.1%
298.3%
Avg
13.0%
88.6%
Low
-19.8%
-5.4%

EPS Forecast

EPS20262027
High-0.66-0.54
Avg-1.16-1.00
Low-1.28-1.27

EPS Growth

EPS Growth20262027
High--
Avg--
Low--
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.